Journal of diabetes and its complications · 2025
Impact of technologies on quality of life in relation to glucose control in patients with type 1 diabetes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Briganti Silvia Irina, Lanza Oreste, Renzelli Valerio, Campagna Giuseppe, Maggi Daria, Caprio Massimiliano, Manfrini Silvia, Strollo Rocky
Аннотация
AIM: To assess the effect of insulin delivery and glucose monitoring technologies on quality of life in relation with glucose control in adults with type 1 diabetes (T1D).
METHODS: This cross-sectional study included 69 adults with T1D (mean age 39.3 ± 12.1 years; 44.9 % females): 36 on multiple daily insulin injections (MDI) and 33 on continuous subcutaneous insulin infusion (CSII). Patient-reported outcomes were assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Diabetes-Specific Quality of Life Scale (DSQOLS), and SF-36. Glucose control was evaluated using HbA1c and CGM metrics.
RESULTS: Individuals in the CSII group reported higher treatment-related satisfaction (p = 0.004), and better disease acceptance (p = 0.004) compared with individuals on MDI, despite similar age, sex or disease duration (p > 0.34). Time in range (TIR) resulted higher in the CSII group than in the MDI group (p = 0.02), while time below range (TBR) resulted higher in the MDI group compared to CSII (p = 0.03). Individuals reporting high satisfaction scores demonstrated better glucose control metrics compared to those with lower satisfaction levels. The association between satisfaction and TIR was relevant, even after adjusting for treatment modality (p = 0.0003).
CONCLUSIONS: Technology may improve quality of life over MDI treatment. Improvement in glucose control may partially account for this effect.
METHODS: This cross-sectional study included 69 adults with T1D (mean age 39.3 ± 12.1 years; 44.9 % females): 36 on multiple daily insulin injections (MDI) and 33 on continuous subcutaneous insulin infusion (CSII). Patient-reported outcomes were assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Diabetes-Specific Quality of Life Scale (DSQOLS), and SF-36. Glucose control was evaluated using HbA1c and CGM metrics.
RESULTS: Individuals in the CSII group reported higher treatment-related satisfaction (p = 0.004), and better disease acceptance (p = 0.004) compared with individuals on MDI, despite similar age, sex or disease duration (p > 0.34). Time in range (TIR) resulted higher in the CSII group than in the MDI group (p = 0.02), while time below range (TBR) resulted higher in the MDI group compared to CSII (p = 0.03). Individuals reporting high satisfaction scores demonstrated better glucose control metrics compared to those with lower satisfaction levels. The association between satisfaction and TIR was relevant, even after adjusting for treatment modality (p = 0.0003).
CONCLUSIONS: Technology may improve quality of life over MDI treatment. Improvement in glucose control may partially account for this effect.
Предметные рубрики MeSH
HumansDiabetes Mellitus, Type 1Quality of LifeFemaleMaleAdultCross-Sectional StudiesInsulinInsulin Infusion SystemsMiddle AgedGlycemic ControlBlood Glucose Self-MonitoringHypoglycemic AgentsBlood GlucosePatient SatisfactionGlycated HemoglobinPatient Reported Outcome MeasuresSurveys and Questionnaires